Olfactomedin 4 regulates migration and proliferation of immortalized non-transformed keratinocytes through modulation of the cell cycle machinery and actin cytoskeleton remodelling.


Journal

Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226

Informations de publication

Date de publication:
01 06 2022
Historique:
received: 03 11 2021
revised: 14 03 2022
accepted: 20 03 2022
pubmed: 27 3 2022
medline: 14 4 2022
entrez: 26 3 2022
Statut: ppublish

Résumé

Olfactomedin 4 (OLFM4), a multifunctional matricellular protein, is involved in regulation of angiogenesis, innate immunity, inflammation, tumorigenesis and metastasis formation via modulation of important cellular processes like adhesion, proliferation, differentiation as well as apoptosis. In our previous work we demonstrated the upregulation of OLFM4 during liver regeneration and cutaneous wound healing. Here we studied the outcomes of OLFM4 downregulation in human immortalized keratinocytes - the HaCaT cells. The suppression of OLFM4 inhibited migration but enhanced the proliferation of these cells. By using proteomic, and phosphoproteomic analysis, we found that OLFM4 downregulation induced changes in the levels of 184 proteins and 348 phosphosites. An integrated pathway analysis suggested that the increased phosphorylation of CDK7 at Ser164 and Thr170 may serve as the key event in the activation of CDK2 and consequent activation of cell cycle progression. Furthermore, the decrease in GIT1 and WAVE2 protein levels were connected to the disorganization of the actin cytoskeleton, reduction of lamellipodia formation at the leading edge of HaCaT cells, and decrease in their migration capacity.

Identifiants

pubmed: 35337817
pii: S0014-4827(22)00104-5
doi: 10.1016/j.yexcr.2022.113111
pii:
doi:

Substances chimiques

Extracellular Matrix Proteins 0
Glycoproteins 0
OLFM4 protein, human 0
olfactomedin 0
Granulocyte Colony-Stimulating Factor 143011-72-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113111

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Claudia Griselda Cárdenas-León (CG)

Department of Cell Biology, Institute of Molecular and Cell Biology, University of Tartu, Estonia.

Mariliis Klaas (M)

Department of Cell Biology, Institute of Molecular and Cell Biology, University of Tartu, Estonia.

Kristina Mäemets-Allas (K)

Department of Cell Biology, Institute of Molecular and Cell Biology, University of Tartu, Estonia.

Terje Arak (T)

Tartu University Hospital, Surgery Clinic, Puusepa 8, 50406, Tartu, Estonia.

Mart Eller (M)

Tartu University Hospital, Surgery Clinic, Puusepa 8, 50406, Tartu, Estonia.

Viljar Jaks (V)

Department of Cell Biology, Institute of Molecular and Cell Biology, University of Tartu, Estonia; Dermatology Clinic, Tartu University Clinics, Tartu, Estonia. Electronic address: viljar.jaks@ut.ee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH